TL;DR: Invitris is a Y Combinator Winter 2023 startup Creating new protein-based drugs at scale, currently active with a team of 6.
Creating new protein-based drugs at scale
Last verified:
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Built by LemStudio
Yes. Invitris was funded by Y Combinator in the Winter 2023 batch. Creating new protein-based drugs at scale
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the ne…
Invitris was part of Y Combinator's Winter 2023 batch.
Invitris has a team of 6 people according to Y Combinator's directory.
Invitris is currently listed as Active with a team of 6 in Y Combinator's directory.
Loading interactive view…